论文部分内容阅读
最近,遗传基因杂交技术合成的人类胰岛素(HIrDNA)应用于临床,使糖尿病在病因、病理生理、治疗诸方面的研究进展极快。由于2.6二磷酸果糖(F_(-2,6)—P_2)的发现和借助于研究它在肝内浓度的增减变化,可了解高血糖素和胰岛素控制肝内葡萄糖利用和生成机制。在糖尿病的病因研究上,抗胰岛抗体(ICA)和抗胰岛细胞膜抗体(ICSA)研究进展较快。特别在日本,Ⅰ型糖尿病(IDDM)发病的早期阶段,这两种抗体检出率相当高,证明胰岛炎症或自身免疫机制可能是大多数IDDM的发病原因。为了IDDM的早期发
Recently, the genetic hybridization of synthetic human insulin (HIrDNA) applied to clinical, diabetes, etiology, pathophysiology, treatment of various aspects of research progress is extremely fast. Because of the discovery of fructose-2.6 diphosphate (F _ (-2,6) -P_2) and by studying its changes in intrahepatic concentrations, it is possible to understand the mechanisms by which glucagon and insulin control intrahepatic glucose utilization and production. In the etiology of diabetes, anti-islet antibody (ICA) and anti-islet cell membrane antibody (ICSA) research progresses rapidly. Especially in Japan, the detection rate of these two antibodies is very high in the early stages of the onset of type 1 diabetes mellitus (IDDM), demonstrating that islet inflammation or autoimmunity may be the cause of most IDDM. In order to IDDM early hair